Array Biopharma Inc (ARRY.OQ) Key Developments | Reuters.com
Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

3.63USD
4:00pm EDT
Change (% chg)

$0.07 (+1.97%)
Prev Close
$3.56
Open
$3.71
Day's High
$3.81
Day's Low
$3.61
Volume
527,399
Avg. Vol
555,527
52-wk High
$7.30
52-wk Low
$2.38

Latest Key Developments (Source: Significant Developments)

Array biopharma submits Binimetinib new drug application to U.S. FDA
Thursday, 30 Jun 2016 04:00pm EDT 

Array Biopharma Inc : Array biopharma submits binimetinib new drug application to u.s. Fda . Binimetinib was generally well-tolerated and adverse events reported were consistent with previous results . There was no statistically significant difference demonstrated in overall survival,median overall survival favored binimetinib arm .Array biopharma submits binimetinib new drug application to u.s. Fda.  Full Article

Merck KGaA partners with Array BioPharma, Pierre Fabre on mCRC phase iii trial
Saturday, 4 Jun 2016 09:23am EDT 

Merck KGaA : Says partners with Array BioPharma and Pierre Fabre to initiate braf-mutant mCRC phase iii trial Further company coverage: [MRCG.DE] ((frankfurt.newsroom@thomsonreuters.com; +496975651270;)).  Full Article

Array BioPharma appoints patricia henahan as chief financial officer
Tuesday, 8 Sep 2015 08:00am EDT 

Array BioPharma:Names patricia henahan as chief financial officer.  Full Article

Array BioPharma enters into asset purchase agreement with Accuratus Lab Services Inc - Form 8-K
Tuesday, 2 Jun 2015 08:01am EDT 

Array BioPharma:Says on June 1 Array BioPharma entered into an Asset Purchase Agreement with Accuratus Lab Services, Inc.Pursuant to which Accuratus acquired certain assets and assumed certain liabilities relating to Array’s chemistry, manufacturing and controls business in a transaction that closed on June 1.Says the sale of the CMC business provides this world-class team the opportunity to grow and achieve continued success, while continuing to provide expert support to Array’s drug discovery and development programs.Transaction included the transfer of equipment, inventory and third party contracts of Array relating to its CMC business as well as Array’s facilities lease in Longmont, Colorado and the retention of approximately 33 Array CMC employees by Accuratus following the closing.Accuratus paid Array a cash purchase price at closing for the CMC assets, and Array is entitled to receive additional consideration for the CMC assets contingent upon achievement of revenue targets for the CMC business during the first and second year following the closing.  Full Article

Array BioPharma Inc updates FY 2015 revenue outlook; EPS outlook below analysts' estimates - Conference Call
Tuesday, 3 Feb 2015 09:00am EST 

Array BioPharma Inc:Says it is looking for revenue to move up reaching $45 mln and loss per share to improve to $0.06 in FY 2015.FY 2015 revenue of $45 mln and EPS of $(0.67) - Thomson Reuters I/B/E/S.  Full Article

Array announces agreement to acquire ENCORAFENIB
Friday, 23 Jan 2015 08:00am EST 

Array BioPharma Inc:Reaches a definitive agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in Phase 3 development.Agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected to close in the first half of 2015.Upon satisfaction of all conditions and closing of the deal, Array will acquire global rights to encorafenib.  Full Article

Array BioPharm Inc announces termination and asset transfer agreement - Form 8-K
Wednesday, 3 Dec 2014 04:06pm EST 

Array BioPharm Inc:Entered into termination and asset transfer agreement dated Nov. 26, 2014 with Novartis Pharma AG and Novartis International Pharmaceutical Ltd.Under Novartis Agreement, Array, Novartis and NIP agreed to terms pursuant to which Array will regain all development and commercialization rights to binimetinib, MEK oncology program that Array had previously licensed to NIP under license agreement dated April 19, 2010.When transactions contemplated by Novartis agreement become effective, existing license agreement will terminate.  Full Article

Array Biopharma Inc gives Q2 2015 loss outlook; revenue outlook below analysts' estimates - Conference Call
Tuesday, 4 Nov 2014 09:00am EST 

Array Biopharma Inc:Expects Q2 2015 revenue to $7 mln and a slightly reduced loss per share to $0.20.Q2 2015 revenue of $8 mln, EPS of $(0.20) - Thomson Reuters I/B/E/S.  Full Article

Array Biopharma Inc gives Q1 2015 guidance below analysts' estimates - Conference call
Tuesday, 12 Aug 2014 09:00am EDT 

Array Biopharma Inc:Sees Q1 2015 revenue and loss per share (EPS) to be similar to Q4 2014.Reported revenue of $6.01 mln and EPS of $(0.22) in Q4 2014.Q1 2015 revenue of $10.06 mln and EPS of $(0.21) - Thomson Reuters I/B/E/S.  Full Article